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Abstract
Abnormal inflammations are central therapeutic targets in numerous infectious and autoimmune diseases. Dendritic cells
(DCs) are involved in these inflammations, serving as both antigen presenters and proinflammatory cytokine providers. As
an immuno-suppressor applied to the therapies of multiple sclerosis and allograft transplantation, fingolimod (FTY720) was
shown to affect DC migration and its crosstalk with T cells. We posit FTY720 can induce an anergy-polarized phenotype
switch on DCs in vitro, especially upon endotoxic activation. A lipopolysaccharide (LPS)-induced mouse bone marrow-
derived dendritic cell (BMDC) activation model was employed to test FTY720-induced phenotypic changes on immature
and mature DCs. Specifically, methods for morphology, nanostructure, cytokine production, phagocytosis, endocytosis and
specific antigen presentation studies were used. FTY720 induced significant alterations of surface markers, as well as decline
of shape indices, cell volume, surface roughness in LPS-activated mature BMDCs. These phenotypic, morphological and
topographical changes were accompanied by FTY720-mediated down-regulation of proinflammatory cytokines, including
IL-6, TNF-a, IL-12 and MCP-1. Together with suppressed nitric oxide (NO) production and CCR7 transcription in FTY720-
treated BMDCs with or without LPS activation, an inhibitory mechanism of NO and cytokine reciprocal activation was
suggested. This implication was supported by the impaired phagocytotic, endocytotic and specific antigen presentation
abilities observed in the FTY720-treated BMDCs. In conclusion, we demonstrated FTY720 can induce anergy-polarization in
both immature and LPS-activated mature BMDCs. A possible mechanism is FTY720-mediated reciprocal suppression on the
intrinsic activation pathway and cytokine production with endpoint exhibitions on phagocytosis, endocytosis, antigen
presentation as well as cellular morphology and topography.
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Introduction
Dendritic cells (DCs) represent a typical cell type participating
in the ‘‘dual-edge sword’’ in immunity. In addition to serving as
professional antigen-presenting cells, involved in beneficial im-
muno-protection, they are also key effector cells in a variety of
detrimental chronic and acute inflammations. For example,
chronic lesion formation in atherosclerosis was found to be
etiologically relevant to DC-induced proinflammatory cytokine
production, especially in terms of synergistically inflammatory
attacks on the vascular walls caused by hypercholesterolemia in
blood and microbial antigens on endothelial cells [1–4]. This is
comparable with more specific findings in acute bacterial
infections [5,6]. When exposed to gram-negative bacteria, the
endotoxin-induced primary activation of DCs is frequently
followed by the formation of desensitized DCs, known as LPS-
tolerance DCs. This mechanism was found pivotal in sepsis
survivors as a negative-feedback mechanism to prevent acute
endotoxic shock [5,6].
These DC-relevant chronic and acute inflammations play
important roles in a number of autoimmune and allergy diseases
as aberrant antigen presentation and/or DC response involves [7].
It was shown self-protein-loaded DCs can trigger autoimmunity
via TLR3 and TLR9 ligations in the development of autoimmune
myocarditis [8]. Similarly, in multiple sclerosis (MS), self-antigen
responsive T cells can be sufficiently primed by DCs to initiate
central nervous system (CNS) inflammation, responsible for
disease progression [9]. This mechanism is further confirmed by
the observation showing the prolonged life span of DCs is
associated with chronic lymphocyte activation and systemic
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relevant inflammations are observed in various allergies. Partic-
ularly, abnormal response of DCs to thymic stromal lymphopoie-
tin is deemed a key mechanism in priming the T helper 2 (Th2)
cells to produce inflammatory cytokines in allergic diseases, such as
asthma, allergic rhinitis and food allergies [12]. Taken these
aspects together, DC-induced inflammation is one of the common
nodes for therapy of the above-mentioned human diseases; and as
proposed by numerous investigations, proper modulation of DCs
to suppress such inflammations is a useful therapeutic strategy
(reviewed in [7,13]).
As a newly approved drug on MS treatment, fingolimod
(FTY720) was firstly synthesized by chemically modifying
myriocin, a metabolite of Isaria sinclairii, used as a component in
traditional Chinese medicine [14]. The major therapeutic
mechanism of FTY720 is to sequester autoimmune T cells in
the secondary lymphoid tissues and reduce the T cell infiltration in
CNS [15–18].
Indeed, the initial efforts on the development of FTY720 were
largely confined in the immune-suppressor effects that are
demanded in tissue and organ transplantations. Although its
efficacy was confirmative, the high dose of application was a
concern, leading to an investigative diversion to treatments of
other diseases, such as MS and cancer (reviewed in [18]).
However, plentiful knowledge was acquired from early studies,
especially in terms of possible functions of FTY720 on DCs. In a
subtle study, with a mixed lymphocyte reaction (MLR) model,
FTY720-treated human DCs exhibited reduced antigen presen-
tation function and altered cytokine production after stimulation
with CD40 ligand-expressing cells [19]. In addition, FTY720 was
found to block DC trafficking that is relevant to its immunosup-
pressive effects [20].
With the rationale above, we posit the effects of FTY720 on
DCs include an anergy-driven polarization mechanism, especially
upon endotoxic activation. Addressing this question is clinically
relevant to propose an expansion of FTY720’s application to
modulate more generalized chronic and acute inflammations,
targeting at DCs. Therefore, we employed a lipopolysaccharide
(LPS)-induced mouse bone marrow-derived dendritic cell (BMDC)
activation model and demonstrated direct effects of FTY720 to
induce anergy-polarization of BMDCs, for the first time, in terms
of nanostructure, biological functions and possible mechanisms.
Results
FTY720 Changes the Surface Phenotypes of BMDCs Upon
LPS Activation
It has been shown FTY720 does not significantly change
phenotypes of both human immature and mature DCs isolated
from peripheral blood, however only decreases CD18 expression
[19]. We posit FTY720 alone should have minimal effects on the
maturation of BMDC; however upon LPS treatment, FTY720 is
able to suppress the LPS-induced maturation. All experiments
mentioned in this section were repeated for 3 times, indepen-
dently.
After being co-treated by granulocyte macrophage colony-
stimulating factor (GM-CSF) and IL-4, mouse bone marrow cells
were differentiated into BMDCs, showing (95.961.7)% positive
for the macrophage/DC lineage marker CD11c (Figure 1A). The
expression of CD11c surface molecules was not significantly
changed in either the LPS- and/or the FTY720- treated groups
(Figure 1A).
LPS treatment was observed to induce typical maturation
phenotypes of BMDCs (Figure 1B–E). First, LPS-treated BMDCs
showed significant up-regulation of MHC II molecule, I-A
d
(Figure 1B), and the expression of co-stimulatory molecules,
including CD86 (Figure 1D) and adhesion molecule CD40
(Figure 1E) (P,0.05, n=3). Thus, the positive control (LPS-
activated mature DC) and negative control (untreated immature
DC) for this experiment were validated by these data. No
significant difference was observed for CD80 expression between
different groups (Figure 1C). Compared with the untreated group,
FTY720 exhibited no considerable changes on the surface
molecules at the major experimental concentration of 500 nM
(Figure 1 A–E). However, comparing with the LPS-treated groups,
FTY720 suppressed LPS-induced BMDC maturation by signifi-
cantly alleviating the expression of I-A
d (Figure 1B), CD86
(Figure 1D) and CD40 (Figure 1E) (P,0.05, n=3).
FTY720 Reverses the Morphological and Topographical
Changes in LPS-activated Mature BMDCs
As shown in Figure 1, FTY720 changed maturation-relevant
surface markers of BMDC upon LPS activation. We further
examined these suppressive functions of FTY720 at a nanos-
tructure level on BMDCs during the inflammatory response upon
LPS-activation BMDCs (Figure 2).
Treated by LPS alone, BMDCs showed increased elongation
morphologies, compared with the untreated and the FTY720
alone group; however these LPS-induced elongations were
suppressed by FTY720 (Figure 2A). We next calculated the cell
shape index (major axis/minor axis) of each group [21]. LPS
treatment increased the shape index by approximate 4 folds,
compared with both the untreated and the FTY720 alone group,
respectively (P,0.05, n=20; Figure 2B). In the LPS+FTY720
group, the shape index was significantly reduced to the level close
to the untreated group (P,0.05, n=20; Figure 2B).
We previously employed atomic force microscopy (AFM) as an
efficient way to topographically investigate the nanostructural
changes in different cell types, especially in DCs [22–24]. A similar
evaluation strategy was used in this study (Figure 2C–F).
Consistent with the shape index results, cells in the untreated
and the FTY720 alone-treated group shared a round-shaped
morphology covering approximately 40640 mm
2 growth area
(Figure 2C and 2D), however the elongated cells are predominant
in the LPS-treated group with a stretching morphology covering
around 70670 mm
2 growth area (Figure 2E). In the LPS+FTY720
treated group, these LPS-mediated DC morphological changes
were reversed to a similar level to the untreated BMDCs
(Figure 2F).
Topographically, FTY720 alone cannot significantly down-
regulate cell volume (Figure 2G), root square mean (RSM)
roughness (Figure 2H) and the peak to valley distance (Figure 2I)
of BMDCs. In contrast, compared with the untreated group, these
parameters were increased by approximately 1.5 folds (P,0.05,
n=10) (Figure 2G–I) in the LPS-treated group, accompanied by a
significant reduction of cellular peak to valley distance (Figure 2I)
(P,0.05, n=10). Both cell volume and RMS roughness upon LPS
activation were suppressed significantly by co-treatment with
FTY720 (P,0.05, n=10; Figure 2G and 2H).
Scanning Electron Microscopic Validation
To validate the cell surface roughness changes observed in AFM
experiments, we further performed scanning electron microscopy
(SEM) (Figure 3). Consistently, dendrites and largely round-shaped
BMDCs were observed in the untreated and FTY720 alone-
treated groups. LPS-activated mature BMDCs exhibited remark-
ably increased number of dendrites, vesicle-abundant surface
structures and dendrite morphologies. However, in the
FTY720 Induces Anergy-Polarized Dendritic Cells
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immature BMDC-like morphologies. This is another visualization
confirmation on the topographical results obtained from AFM
experiments.
Cell Viability Assay
As we observed significantly suppressive modulation of FTY720
on BMDCs, especially in terms of LPS mediated activation, we
have to rule out the possible cytotoxicity effects of the drug before
providing further biological mechanisms. We addressed this
question by cell viability assays on FTY720-treated bone marrow
cells and BMDCs, respectively (Figure 4). No cytotoxicity was
observed in mouse bone marrow cells treated by FTY720 at
concentrations of 0, 0.1, 0.5, 1.0 and 2.0 mM, however higher
concentrations of FTY720 could induce significant cytotoxicity
(P,0.05, n=3; Figure 4A). Regarding BMDCs, FTY720 did not
show significant cytotoxicity effects at all tested concentrations in
the MTT assay (Figure 4B). With concentrations at 1.0, 5.0 and
Figure 1. FTY720 alters the surface phenotype of mouse bone marrow-derived dendritic cells upon LPS activation. Expression of
CD11c (A), MHC II molecule I-A
d (B), CD80 (C), CD86 (D) and CD40 (E) was shown in their respective panels. For these assays, mouse bone marrow
cells were differentiated for 6 d to prepare BMDCs that were exposed to LPS (1 mg/mL) and/or FTY720 (500 nM) for additional 24 h. Representative
results out of three independent experiments were shown. The mean fluorescence intensities (MFI) of each marker were analyzed for statistical
difference. *P,0.05, n=3.
doi:10.1371/journal.pone.0034830.g001
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greater than 17%, 23% and 65%, respectively (Figure 4C).
However, FTY720 did not induce BMDC cell death at the
concentration of 500 nM, which is the primary concentration used
in most of the experiments in this study (Figure 4C).
FTY720 Suppresses the Cytokine Production in BMDCs
Upon LPS Activation
From the topographical and morphological experiments, we
observed abundant secretory vesicle-like structures in LPS-treated
BMDCs, which were considerably different from other experi-
mental groups. We posit this could imply a secretory suppression
mechanism in FTY720-modulated BMDCs. Thus, we tested the
cytokine concentrations by cytometric bead array (CBA) analysis
in the culture supernatants to address this question (Figure 5).
Three independent experiments were performed on these
experiments.
First, FTY720 alone showed an anti-inflammation phenotype
switch, compared with the untreated BMDCs, evidenced by
significant up-regulation of IL-10 secretion (P,0.05, n=3;
Figure 5A), as well as significant down-regulation of IL-6 and
MCP-1 production (P,0.05, n=3; Figure 5B and 5F, respective-
ly). Second, BMDCs showed typical activation phenotypes,
exhibiting approximately 1.5–6 fold increases of cytokine produc-
tion upon LPS activation, including IL-10, IL-6, TNF-a, IL-12
and MCP-1 (P,0.05, n=3; Figure 5A–D and 5F, respectively).
Third, co-treatment with FTY720 suppressed all these LPS-
induced cytokine productions, significantly (P,0.05, n=3;
Figure 5A–D and 5F). Finally, no significant difference was
observed for IFN-c production in all experimental groups
(Figure 5E).
FTY720 Suppresses Phagocytosis and Endocytosis of
BMDCs Accompanied by Inhibition of CCR7 and NO
Production
It is known that LPS up-regulates CCR7 expression [25], which
is a versatile molecule relevant to migration, maturation and
endocytosis of DC [26–28]. This activation is in part due to nitric
oxide (NO) induction, although ambiguous reports indicated
diverted functions of NO when different doses or treatment
Figure 2. Topographical and morphological changes of BMDCs upon LPS-activation are reversible by FTY720. (A) Morphologies of
LPS- and/or FTY720- treated BMDCs. Day 6 BMDCs were exposed to LPS (1 mg/ml) and/or FTY720 (500 nM) for additional 48 h, followed by
microscopic observations. Scale bar =20 mm. (B) Statistical results on the shape indices of each group. *P,0.05, n=20 (20 cells randomly selected
from high power fields from 3 separate experiments). Atomic force microscope observations on the untreated (C), FTY720 alone (D), LPS alone (E)
and LPS+FTY720- (F) treated groups were shown as representative images. Enlarged areas were indicated in squares in dark and green, respectively.
The statistical results of the cell volume (G), RMS roughness (H) and peak to valley distance (I) are analyzed and shown in histograms. Data are shown
as mean 6 SEM. *P,0.05, n=10 (10 cells randomly selected from 3 separate experiments).
doi:10.1371/journal.pone.0034830.g002
Figure 3. Scanning electron microscopic observation. Day 6 BMDCs were treated with LPS (1 mg/mL) and/or FTY720 (500 nM) for additional
48 h before SEM observation. Scale bar=5 mm.
doi:10.1371/journal.pone.0034830.g003
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mediated proinflammatory response partially by down-regulating
phagocytosis, endocytosis, CCR7 and NO production. Therefore,
these phenotypes were examined and all these experiments were
performed for three times, independently (Figure 6).
Treatment with FTY720 alone was observed to be sufficient to
down-regulate both CCR7 mRNA transcription and NO secretion
of BMDCs, significantly (P,0.05, n=3; Figure 6A and 6B). LPS
stimulation significantly up-regulated CCR7 mRNA and NO
production for approximately 1.5 folds as anticipated (P,0.05,
n=3; Figure 6A and 6B). However, both LPS-induced increases of
CCR7 mRNA and NO production in BMDCs were significantly
suppressed by co-treatment with FTY720 (P,0.05, n=3;
Figure 6A and 6B).
After 1 h exposure to fluorescent beads for phagocytosis assay,
the immature BMDCs generally showed higher proportion of
phagocytotic cells than the LPS alone and the FTY720 alone-
treated cells (Figure 6C). Statistically, the total rate of the
phagocytotic cells in the untreated group was (61.562.1)%,
significantly higher than those in the LPS-treated (51.964.1)%
and the FTY720 alone- treated (33.262.2)% groups (P,0.05,
n=3; Figure 6C).
We next analyzed fluid-phase endocytosis of BMDCs by tracing
internalization of FITC-conjugated-dextran, a component of
endosome [30]. The total rates of the endocytotic cells in the
untreated and the LPS-treated groups were (92.362.7)% and
(88.361.6)%, respectively, both significantly higher than the
FTY720 alone-treated (76.362.6)% group (P,0.05, n=3;
Figure 6D).
FTY720 Mitigates Specific Antigen Presentation Ability of
BMDCs
As demonstrated above, maturation associated phenotypes,
including topography, morphology, phagocytosis and endocytosis
of BMDCs were down-regulated by FTY720. These phenomena
imply a collective endpoint behavior of BMDC anergy to
inflammation and adaptive immunity. Therefore, we hypothesize
these anergy-polarized phenotypes should be accompanied by
mitigated abilities of specific antigen presentation ability of
BMDCs. Thus, we isolated lymphocytes from transgenic mice,
DO11.10 strain, with transgenic T cell receptors that are reactive
to ovalbumin (OVA) peptide 323–339 antigen, specifically. By
testing the cell proliferation behavior of these OVA-specific T cells
with CFSE-staining flow cytometry, the OVA presentation
abilities of BMDCs with or without FTY720 treatment could be
determined (Figure 7). Results were acquired from three indepen-
dent experiments.
Figure 4. Cell viability determination. (A) MTT assays on the bone marrow cells. Mouse bone marrow cells were isolated and exposed to FTY720
with different concentrations for 48 h. Cytotoxicity was indicated by the ratio of ODFTY720 to ODcontrol. Data are shown as mean 6 SEM. *P,0.05, n=3.
(B) MTT assays on BMDCs. Day 6 BMDCs were treated with FTY720 at concentrations of 0, 0.1, 0.5 and 1.0 mM for 48 h. Data are shown as mean 6
SEM. *P,0.05, n=3. (C) Apoptosis assays on BMDCs. The cell death rates of BMDCs was determined by Annexin V-FITC and PI staining flow
cytometry. Cells were treated with FTY720 for 48 h at concentrations ranged from 0.5 to 10 mM.
doi:10.1371/journal.pone.0034830.g004
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cultivation with BMDC with no presence of OVA treatment
(Figure 7A&7B). Similarly, no lymphocyte proliferation was
observed in the OVA- (Figure 7A) or OVA peptide 323–339-
(Figure 7B) treated DO11.10 mouse lymphocytes groups. Both of
these groups were served as negative control groups in the
experiments of this section. As a positive control, DO11.10
lymphocytes can proliferate responsive to the stimulation conca-
navalin A (Con A) alone (Figure 7A&7B). Untreated BMDCs
exhibited both OVA protein (Figure 7C) and OVA peptide 323–
339- (Figure 7D) presentation ability by significantly promoting
proliferation of DO11.10 mouse lymphocytes (P,0.05, n=3). If
BMDCs were pre-treated with FTY720, this antigen presentation
ability was significantly reduced (P,0.05, n=3; Figure 7C&7D).
To determine the feature of T cell polarization in OVA peptide
323–339-induced DO11.10 lymphocyte proliferation, we tested
the production of two Th1 cytokines, IL-2 (Figure 7E) and IFN-c
(Figure 7F). Upon OVA peptide 323–339 treatment, the
production of both cytokines were significantly up-regulated in
the untreated BMDC co-cultivation group, compared with the two
negative control groups (P,0.05, n=3; Figure 7E&7F). However,
if co-cultivated with FTY720-treated BMDCs, this up-regulation
of the two cytokines was significantly alleviated (P,0.05, n=3;
Figure 7E&7F).
Discussion
The overall results of this study suggested FTY720 induces an
anergy-polarized effect on BMDCs, exhibiting molecular, topo-
graphical, morphological and functional changes. As a widely
used Chinese herbal medicine, I. sinclairii is believed to be able to
put down ‘‘the fire’’, an ancient way in China to describe
inflammations in human body [31]. Actually, this was found
largely due to the immune-suppressive functions of myriocin, the
pre-drug of FTY720, abstracted from I. sinclairii [32]. Concep-
tually, our findings in this study imply a consistent application of
FTY720 to chronic and acute inflammatory diseases, however
revealed DCs are a direct target cell type for calming down these
aberrant inflammations. Therefore, we provided an insight of
Figure 5. Cytometric Bead Array analysis. CBA assays on IL-10 (A), IL-6 (B), TNF-a (C), IL-12 (D), IFN-c (E) and MCP-1 (F) were shown in their
respective panels. For these assays, Day 6 BMDCs were treated with LPS (1 mg/mL) and/or FTY720 (500 nM) for 24 h. The culture supernatants of each
group were subjected to CBA analysis by flow cytometry. Data are shown as mean 6 SEM. *P,0.05, n=3. The cytokine concentrations were
calculated from the standard curve (R
2.0.95) via data analysis by a four parameter linear fitting program provided by the manufacturer.
doi:10.1371/journal.pone.0034830.g005
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transplantation studies.
We demonstrated FTY720 alone does not affect the surface
maturation markers of BMDCs, including CD11c, MHC II
molecules, CD80, CD86 and CD40. Indeed, these results are
comparable with a number of investigations on FTY720 and DCs
[19,33,34], thus also serving as a confirmation of valid preparation
of BMDCs for the entire experiments in this study. These
unimpaired surface markers are also indicators of non-toxic effects
of FTY720 on BMDCs, which was confirmed by the subsequent
Figure 6. CCR7 transcription, NO production as well as phagocytosis and endocytosis of BMDCs. (A) CCR7 mRNA production analysis.
Day 6 BMDCs were treated with LPS (1 mg/mL) and/or FTY720 (500 nM) for 24 h. Total mRNA were extracted, reverse transcripted and quantified by
the real-time PCR. *P,0.05, n=3. (B) Nitric oxide production assays. Supernatants of cells with similar treatments were obtained and analyzed by
diazotization reaction and colorimetry. *P,0.05, n=3. (C) Phagocytosis assay of BMDCs. Day 6 BMDCs were treated with LPS (1 mg/ml) alone or
FTY720 (500 nM) alone for 24 h and subjected to fluorescence-conjugated beads uptake assays. Representative of results on the percentage of
phagocytes were shown in each flow chart. Statistical analysis on the percentage of phagocytotic cells were presented as mean 6 SEM. *P,0.05,
n=3. (D) Endocytosis assay of BMDCs. Similar experimental design to (C) were employed. Cells were treated with FITC-conjugated dextran and
analyzed by FACS. Representative results on the percentage of endocytotic cells were shown. Statistical data were presented as mean 6 SEM.
*P,0.05, n=3.
doi:10.1371/journal.pone.0034830.g006
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experimental concentration of FTY720 did not induce cytotoxicity
on BMDCs. These phenotypic profiling and non-cytotoxic results
served as a valid basis of following functional investigations.
We showed in this study, the both LPS-induced surface
phenotype and nanostructure changes of BMDCs were suppressed
by FTY720. Cellular surface topographies have been recognized
as markers of both cell functional differentiation [23,24] and
maturation, specifically for DCs [22]. Heterogeneous enlargement
of cell volume was frequently observed in activated-T cells [35,36],
DCs upon maturation [22,37] and macrophages in infections
[38,39]. These changes in cell size are often accompanied by
cellular height (peak to valley distance), cell surface ruffle (RMS
roughness) and protrusion formation (dendrites in BMDCs) [22–
24]. These parameters are particularly useful in quantitative
evaluations on the relevance of cell structures and diseases [40].
According to the AFM observations in this study, the LPS-induced
maturation of BMDCs was mitigated by FTY720 in the ways of
decreasing surface particles and containing cellular enlargement.
This was confirmed by the SEM assays and supported by
additional information acquired from the shape index analysis.
Numerous secreted vesicles, such as microvesicles (MVs), exo-
somes, membrane particles and apoptotic vesicles exist on different
cell types; they are crucial transporters in cellular crosstalk [41,42]
(reviewed in [43]). Other than MVs (100–1,000 nm in diameter)
[44], the sizes of all other vesicles are in the range of 20 to 500 nm
in diameter (reviewed in [43]). As shown in the AFM and SEM
results, the size of surface particles in LPS-activated BMDCs is
approximately 500 to1,000 nm in diameter. Therefore, most of
these structures are in MVs, according to particle sizes.
The possible suppression of MVs by FTY720, observed in this
study, led us to hypothesize a drug-mediated BMDC anergy upon
LPS activation. Favorably, we identified FTY720-induced overall
down-regulation of cytokine production in LPS-activated BMDCs,
including IL-10, IL-6, IL-12, TNF-a and MCP-1, for the first
time. As a ligand of CD14, it is known that bacterial LPS induces a
large amount of cytokine production, including TNF-a, IL-6, IL-8
and IL-12 [45], as well as IL-10 [46] and MCP-1 [47]. Down-
regulating these cytokines by FTY720 in BMDCs is potentially
significant in therapies of diseases characterized by over-activa-
tions. For example, HIV-1 infected macrophage and DCs are
important suppliers of proinflammatory cytokines, including TNF-
a, IL-6 and IL-1b, which are etiologically relevant to HIV-1
associated neurodegenerative diseases (HAND) [48–53]. We
previously reported that Copexone, another approved drug on
MS treatment, suppresses the neurotoxic effects of HIV-1 infected
macrophages via increasing IL-10 expression and macrophage
phenotype switch [52]. Interestingly, this is in agreement with the
significant IL-10 up-regulation as well as Il-6 and MCP-1 down-
regulation in the FTY720 alone-treated group, observed in this
study.
Regarding the phenotypic switch from maturation to anergy-
polarization of FTY720-treated BMDCs upon LPS activation, we
posit the mechanism should partly rely on the NO intrinsic
pathway. This is because as a consequence of inflammation,
proinflammatory cytokines are enhancers of NO production
[29,54]. In turn, NO is a potent inducer of production of these
cytokines, including TNF-a and IFN-c [55,56]. Under normal
conditions, this positive feedback loop ends in where NO
concentration becomes high enough to induce cytotoxic effects
on immune cells. Therefore, reciprocal activation between NO
and proinflammatory cytokines, has been identified as a mecha-
nism to maintain inflammatory microenvironment [56]. In this
study, we demonstrated an FTY720-suppressed NO production
with or without LPS-treatment, which supported the above-
mentioned reciprocal functionality argument. This was further
supported by the FTY720-induced suppression of IL-6, TNF-a
and MCP-1observed in this study.
NO is also known to induce endocytosis via cGMP pathways
[57], which is partially relevant to a chemokine receptor, CCR7
[28]. This is because CCR7 is not only a migration-associated
molecule, it can also stimulate protrusion formation via binding
CCL19 that plays important roles in endocytosis [58]. Reduction
of protrusions on DCs is a phenotypic indicator of impaired
antigen presentation [59]. Favorable to these theories, we
demonstrated FTY720 can down-regulate CCR7 transcription,
along with impairing the phagocytotic and endocytotic capacities
of BMDCs and reduction of dendrites. These mechanisms of
anergy-polarized DCs were further supported by showing that
FTY720 suppresses specific antigen presentation function of
BMDCs, shown in this study.
The translational potential of FTY720-induced anergy-polari-
zation, proposed in this study, is supported by recent in vivo
investigations. As an example, local application of FTY720 to the
lung was reported to contain experimental asthma via targeting at
dendritic cell function [33]. This anti-allergic airway inflammation
activity of FTY720 could be explained partially by a later finding
of the anti-DC migration and chemokine receptor expression
mitigation effects of the drug [60]. Recent studies indicated these
suppressive effects of FTY720 may not lead to a systematic
immunodeficiency. In a subtle study, the cellular and humoral
immune responses to influenza vaccine were found unmitigated in
MS patients treated with FTY720, and these response capacities
are comparable to healthy subjects [61].
In conclusion, we demonstrated FTY720 can induce an anergy-
polarized phenotype switch of BMDCs characterized by the
impaired functions of NO production, CCR7 transcription,
phagocytosis, endocytosis and antigen presentation. Upon LPS
activation, this polarization became apparent by additionally
exhibiting declined shape index, decreased topographical param-
eters as well as proinflammatory cytokines. One of the possible
mechanisms of this anergy induction is FTY720 suppresses the
reciprocal activation between NO and cytokines in BMDCs that
mitigates CCR7 transcription, phagocytosis and endocytosis,
resulting in an endpoint phenotype changes in cellular morphol-
ogy and topography.
Figure 7. FTY720 suppresses the specific antigen presentation ability of BMDCs. (A) FTY720 impaired the ovalbumin (OVA) protein
presentation ability of BMDCs. Lymphocytes from transgenic mice DO11.10 strain, producing T cells specifically recognizing OVA epitope at amino
acid sequence from 323 to 339, were obtained from lymph node. Day 6 BMDCs pre-treated with or without FTY720 (500 nM) were employed to
present OVA protein and co-cultivated with DO11.10 lymphocytes. T cell proliferation was subsequently analyzed by CFSE-staining flow cytometry;
the fluorescence was detected at FL1 channel. A Con A-induced T cell proliferation model was adopted as a positive control. As negative controls,
DO11.10 lymphocytes were exposed either to BMDCs with no presence of OVA, or to OVA with no BMDC co-cultivation. (B) Confirmative assays with
OVA peptide 323–339. Similar experimental design to (A) was employed, however OVA peptide 323–339 was used. Statistical results of the
percentages of proliferative OVA (C) and OVA peptide 323–339 (D) -responsive T cells were shown. (E) The production of supernatant IL-2. (F) IFN-c
secretion. Statistical data were presented as mean 6 SEM. *P,0.05, n=3. **P,0.05, n=3, compared with the negative control groups.
doi:10.1371/journal.pone.0034830.g007
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BMDC Preparation
All animal care and experimental procedures were performed in
accordance with protocols approved by the Institutional Animal
Care & Use Committee (IACUC) of Jinan University. Specific
pathogen free (SPF) female Balb/c mice, 6–8 weeks old, were
purchased from the Experimental Animal Center of Southern
Medical University (Guangzhou, Guangdong, China). Bone
marrow cells were harvested from mouse femurs and tibias, and
treated with red blood cell lysis buffer (Invitrogen, Beijing, China),
as described previously [39]. Cells were plated in six-well plates at
1610
6 cells/well and were allowed to attach to the culture surface
for 6 h in RPMI complete medium, RPMI 1640 medium
supplemented with 10% (V/V) fetal bovine serum (FBS), 4 mM
L-glutamine, 25 mM HEPES (pH 7.2), 100 U/mL penicillin and
100 mg/mL streptomycin (all from Invitrogen), as well as 50 mM
b-mercaptoethanol (Sigma-Aldrich, St Louis, MO, USA). Non-
adherent cells were then removed and the residual bone marrow
cells were cultured in BMDC differentiation medium, RPMI
complete medium supplemented with 20 ng/mL recombinant
murine GM-CSF and 20 ng/mL recombinant murine IL-4 (both
from PeproTech, Rocky Hill, NJ, USA). On Day 6 post-
differentiation, BMDCs were acquired and used for subsequent
experiments on FTY720 (Nanjing Ange Pharmaceutical Co., Ltd,
Nanjing, Jiangsu, China) and/or LPS (Sigma).
BMDC Surface Marker Detection
BMDCs were collected and washed once with PBS, followed by
antibody labeling at 4uC for 30 min, 5610
5 cells/sample. Cells
were then washed and re-suspended in 300 mL of washing buffer
(0.5% FBS and 0.05% sodium azide in PBS), and analyzed by a
FACSCalibur flow-cytometer (Becton Dickinson, Beijing, China).
Antibodies used were uorescein isothiocyanate (FITC)-conjugate
anti-mouse CD11c mAbs, as well as phycoerythrin (PE)-conjugat-
ed anti-mouse I-A
d, anti-mouse CD40, anti-mouse CD80 and
anti-mouse CD86 mAbs (BD Biosciences Pharmingen, San Diego,
CA, USA). Fluorescence activated cell sorter (FACS) data were
analyzed by FlowJo software version 7.6.5 (Treestar, Inc., San
Carlos, CA, USA).
Atomic Force Microscopy
AFM observation on BMDCs was performed as previous
described with minor modifications [22,24]. In brief, BMDCs
were cultured on cover glasses (Fisher Scientific, Fair Lawn, NJ,
USA) pre-positioned in six-well plates. Sample preparation
followed the procedure of 3 gentle washes with PBS, addition of
fixative buffer (4% glutaraldehyde in PBS, 10 min), 6 gentle
washes with distilled water and natural dry-off. An atomic force
microscope (AUTOPROBE CP, Thermomicroscopes, Sunnyvale,
CA, USA) was then employed for cell topographical observations
at room temperature under tapping scanning mode. The
curvature radius of the silicon nitride tip (Park Scientific
Instruments, Thermomicroscopes) was close to 10 nm; and the
force constant was 2.8 N/m, approximately. All AFM images were
analyzed by the Proscan Image Processing software version 2.1
(Thermomicroscopes).
Scanning Electron Microscopy
BMDCs were allowed to grow on poly-l-lysine–coated cover
glasses (Fisher Scientific) before being fixed with 2.5% (v/v)
paraformaldehyde in PBS for 10 min at room temperature. After
3 times PBS washes, cells were subjected to sequential dehydration
with gradient ethanol (50%, 70%, 90% and 3 times 100%,
respectively; 5 min for each procedure), followed by isoamyl
acetate treatments (3 times, 5 min for each). Critical point drying
with carbon dioxide was then performed, and samples were
installed to stub holders followed by gold painting before
observation with a scanning electron microscope (ESEM-30,
Philips, Mahwah, NJ, USA).
MTT Assay
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assays for cytotoxicity evaluation was performed as
previously described [36]. In brief, cells were incubated with
MTT (5 mg/mL) solution for 4 h, followed by addition of DMSO
at 100 mL per well. MTT formazan crystals were dissolved by
shaking on an orbital shaker for 15 min. The absorbance was
measured at 570 nm with a microplate reader (Bio-Rad,
Shanghai, China).
Apoptosis Assay
Cells were washed for two times with PBS and resuspened in
100 mL binding buffer (10 mM Hepes [NaOH pH 7.4], 140 mM
NaCl, 2.5 mM CaCl2). Cells were incubated with 5 mL Annexin-
V FITC (BD Pharmingen) per 5610
5 cells for 15 min, followed by
addition of 3 mL propidium iodide (PI) buffer (50 mg/mL PI in
PBS). FACS assay was then performed to detect Annxin-V at FL1
and PI at FL2 channels. Data were analyzed by FlowJo software;
apoptotic cells were distinguished as Annexin-V
+PI
2, while
necrotic cells as Annexin-V
+PI
+.
Cytometric Bead Array
Cytokine secretions of BMDCs were analyzed by mouse
inflammation CBA Kit (BD Pharmingen) following the procedure
as previously described [36]. This technology allows detecting six
cytokines (IL-6, IL-10, MCP-1, IFN-c, TNF-a, and IL-12p70),
simultaneously. Supernatants from different cell cultures were
collected and aliquoted for cytokine assay. Captured bead reagent
was applied to the mixture of 50 mL sample and PE-detection
antibody. The reaction lasted 3 h in the dark at room
temperature. All unbound antibodies were removed by addition
of 1 mL wash buffer following by centrifuging. Captured beads
were then re-suspended with 300 mL wash buffer and analyzed by
FACS (BD). Six standard curves were acquired for each
experiment by four-parameter linear fitting on the concentrations
of serially diluted standards ranging from 10–5000 pg/mL.
Real-time PCR for CCR7 mRNA Assay
The expression of CCR7 mRNA of BMDCs was detected by
SYBR Green-based real-time (RT)-PCR. Total RNA was
extracted from cells by trizol lysis, followed by purification with
Qiagen RNeasy spin columns (Qiagen, Shanghai, China).
Synthesis of cDNA was performed by using the PrimScriptH
Reverse Transcriptase reagent kit (TaKaRa, Dalian, Liaoning,
China). A mixture of 4 mL diluted cDNA, 16 mL of SYBR Green
RealMasterMix (Tiangen Biotech, Beijing) and 150 nM of each
primer, was then prepared and subjected to RT PCR analysis with
an ABI 7500 PCR device (Applied Biosystems, Foster City, CA,
USA). Primer sequences for CCR7 included sense strand 59-
GCGGAACAAGGCCATCAAGG-39 and antisense strand 59-
GACGGAGGCCAGGCTGTAGG-39; Primers for b-actin in-
cluded sense strand 59-ACCGCTCGTTGCCAATAGTG-39and
antisense strand 59-CTTCTCCATGTCGTCCCAGT-39. The
PCR procedure was 10 min/95uC, followed by 30 cycles of
94uC/15 s, 60uC/15 s and 68uC/30 s, and ended by 72uC/30 s.
The relative expression level of the target genes was computed
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software version 1.3.1 (Applied Biosystems).
Intracellular NO Assay
NO formation was determined by using a Griess reagent kit
(Promega, Shanghai, China) according to the manufacturer’s
instructions. Briefly, 50 mL of culture supernatant was mixed with
50 mL Griess reagent and incubated at room temperature for
10 min. Optical density value was than measured at 540 nm with
a microplate reader (Bio-rad). Serially diluted Griess reagent
standards were used in each experiment.
Phagocytosis Assay
BMDCs were treated with 1.0 mm carboxylate-modified yellow-
green fluorescent FluoSpheresH beads (Molecular Probes, Invitro-
gen) for 60 min at 37uC. Cells were washed for three times with
cold PBS and analyzed by FACS (BD). The phagocytotic ability
was evaluated by analyzing fluorescence at FL1 channel.
Endocytosis Assay
BMDCs were exposed to 0.1 mg/mL FITC-conjugated dextran
(Sigma) for 2 h at 37uC. Cells were washed for three times with
cold PBS and analyzed by FACS (BD). The endocytotic ability was
evaluated by analyzing fluorescence at FL1 channel.
Specific Antigen Presentation Ability
SPF level transgenic mice, DO11.10 strain, were purchased
from Model Animal Research Center of Nanjing University
(Nanjing, Jiangsu, China). DO11.10 lymphocytes were isolated
and subjected to CFDA-SE (Invitrogen) staining following the
procedure as described previously [36]. Cells were plated in 96-
well plates at 5610
5 cells/well in OVA- (100 mg/mL; Sigma) or
OVA peptide 323–339- (100 mg/mL; GL Biochem Ltd., Shang-
hai, China) containing medium. BMDCs (if added) were applied to
the DO11.10 lymphocyte cultures at 5610
4 cells/well to present
OVA or OVA peptide 323–339 to OVA-specific T cells. Activated
T cells were continuously cultured for 4 d before analyzing their
CFSE fluorescence intensity with FACS (BD). The lower CFSE
mean fluorescence intensity (MFI) at FL-1 channel detected, the
higher T cell proliferation rate it represents. A Con A-stimulated T
cell proliferation model, as described previously [36], was
employed as a positive control of this experiment.
ELISA
IL-2 and IFN-c concentrations in culture supernatants were
analyzed by ELISA kits (BD Pharmingen) according to the
manufacturer’s instructions. Briefly, 100 mL of serially diluted
standards or samples were applied to 96-well capture plates and
incubated for 2 h at room temperature. After 7 washes, detection
antibody and horseradish peroxidase reagents were added into
each well; plates were incubated for 1 h at room temperature
before another 7 washes. 100 mL substrate was then applied to
each well and the reaction was terminated by 50 mL Stop Solution
provided by the kits. Absorbance was detected by a microplate
reader (Bio-rad) at 450 nm.
Statistics
Data were analyzed for statistical significance either by two-
tailed Student’s t-test or one-way ANOVA with Bonferroni post hoc
multiple comparisons using GraphPad Prism version 5.02
(GraphPad Software, Inc., San Diego, CA, USA). Significant
difference was accepted when P,0.05.
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